Search Within

Nikoletta Lendvai

Formats
  1. Meeting Abstract (71)
  2. Journal Article (33)
  3. Research Letter (2)
Groups
  1. Center for Hematologic Malignancies (106)
  2. Department of Medicine (106)
  3. Hematologic Malignancies, Division of (106)
  4. Myeloma (106)
  5. Hematologic Malignancies Research (77)
  6. Survivorship Research (74)

More Groups

People
  1. Alexander Lesokhin (71)
  2. Hani Hassoun (70)
  3. Heather Landau (68)
  4. Sergio Giralt (67)
  5. David Chung (61)
  6. Carl Landgren (53)

More People

Years
  1. 2022 (1)
  2. 2021 (1)
  3. 2020 (7)
  4. 2019 (7)
  5. 2018 (14)
  6. 2017 (13)

More Years

Publications
  1. Blood (46)
  2. Biology of Blood and Marrow Transplantation (14)
  3. Leukemia and Lymphoma (9)
  4. Bone Marrow Transplantation (6)
  5. Journal of Clinical Oncology (6)
  6. Clinical Lymphoma, Myeloma and Leukemia (5)

More Publications

Publishers
  1. American Society of Hematology (47)
  2. Elsevier Inc. (21)
  3. Nature Publishing Group (10)
  4. Taylor & Francis Group (9)
  5. American Society of Clinical Oncology (6)
  6. Ferrata Storti Foundation (5)

More Publishers

Results (106)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Continuous treatment with lenalidomide plus low-dose dexamethasone (Ld) versus Ld induction followed by autologous stem cell transplant (ASCT) in patients with newly diagnosed multiple myeloma (NDMM): A pooled analysis of two randomized clinical trials
    Meeting Abstract

    Lentzsch, S.; Villanueva, N.; Nguyen, J.; Landau, H.; Lendvai, N.; Miao, S.; Schecter, J. M.; Reyna, M.; Mapara, M. Y.; Redner, R. L.; more...
    Blood (2015)

    Fulltext@MSK | Save
  • Incidence and management of proteasome inhibitor-related cardiotoxicity in multiple myeloma patients at Memorial Sloan Kettering Cancer Center
    Meeting Abstract

    Land, J.; Afifi, S.; Adel, N. G.; Devlin, S.; Arora, A.; Lendvai, N.; Landgren, O.
    Blood (2015)

    Fulltext@MSK | Save
  • Induction with bortezomib and dexamethasone (BD) followed by risk adapted high dose melphalan and autologous stem cell transplantation and BD consolidation in patients with AL amyloidosis: A phase II feasibility study
    Meeting Abstract

    Landau, H.; Montanez, N.; Cowan, A.; Hoover, E.; Flombaum, C.; Liu, J.; Maurer, M.; Lendvai, N.; Landgren, O.; Giralt, S. A.; more...
    Blood (2015)

    Fulltext@MSK | Save
  • The long PD-1 receptor binding kinetics of nivolumab may increase efficacy of subsequent therapy in relapsed and refractory multiple myeloma patients
    Meeting Abstract

    Funt, S. A.; Page, D. B.; Cattry, D.; Lendvai, N.; Hassoun, H.; Landgren, O.; Borrello, I. M.; Lesokhin, A. M.
    Blood (2015)

    Fulltext@MSK | Save
  • Phase 2 study of carfilzomib (CFZ) with or without filanesib (FIL) in patients with advanced multiple myeloma (MM)
    Meeting Abstract

    Zonder, J. A.; Usmani, S.; Scott, E. C.; Hofmeister, C. C.; Lendvai, N.; Berdeja, J. C.; Anderson, L. D.; Hari, P.; Singhal, S.; Orloff, G.; more...
    Blood (2015)

    Fulltext@MSK | Save
  • A dose finding phase II trial of isatuximab (SAR650984, anti-CD38 mAb) as a single agent in relapsed/refractory multiple myeloma
    Meeting Abstract

    Martin, T.; Richter, J.; Vij, R.; Cole, C.; Atanackovic, D.; Zonder, J.; Kaufman, J. L.; Bensinger, W.; Dimopoulos, M. A.; San Miguel, J.; more...
    Blood (2015)

    Fulltext@MSK | Save
  • Role of histone deacetylase inhibitors in relapsed refractory multiple myeloma: A focus on vorinostat and panobinostat
    Journal Article

    Afifi, S.; Michael, A.; Azimi, M.; Rodriguez, M.; Lendvai, N.; Landgren, O.
    Pharmacotherapy (2015)

    Fulltext@MSK | Save
  • A multicenter, randomized, open-label, phase 2 study of carfilzomib with or without ARRY-520 (filanesib) in patients with advanced multiple myeloma
    Meeting Abstract

    Zonder, J. A.; Raje, N. S.; Scott, E. C.; Hofmeister, C. C.; Lendvai, N.; Anderson, L. D.; Hari, P.; Orloff, G. J.; Berdeja, J. G.; Singhal, S.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Beyond consolidation: Auto-SCT and immunotherapy for plasma cell myeloma
    Journal Article

    Lendvai, N.; Cohen, A. D.; Cho, H. J.
    Bone Marrow Transplantation (2015)

    Fulltext@MSK | Save
  • Minimal residual disease in multiple myeloma: Bringing the bench to the bedside
    Journal Article

    Mailankody, S.; Korde, N.; Lesokhin, A. M.; Lendvai, N.; Hassoun, H.; Stetler-Stevenson, M.; Landgren, O.
    Nature Reviews Clinical Oncology (2015)

    Fulltext@MSK | Save